Hugh McMillan
Investigator
Professor, Pediatric Neurology, University of Ottawa
Pediatric Neurologist and Neuromuscular specialist at the Children’s Hospital of Eastern Ontario
NMD4C Involvement: Pillar 2: Clinical Research
Email HughBiography
Dr. McMillan is a Pediatric Neurologist with specialization in Clinical Neurophysiology and Neuromuscular medicine at the Children’s Hospital of Eastern Ontario. He is a Professor in the Department of Pediatrics, Faculty of Medicine at the University of Ottawa. He holds a Clinical Research Chair (Level 2) at the University of Ottawa and is a Clinical Investigator at the CHEO Research Institute
He has been an author of over 125 publications in peer-review journals and was a co-editor of a Pediatric Electromyography textbook. He is also a leader in clinical and translational research in pediatric neurology & neuromuscular medicine.
Dr. McMillan completed a Neuromuscular and Neurophysiology Fellowship at Boston Children’s Hospital, Harvard University and the Lahey Clinic, Tufts University; a Pediatric Neurology Residency at the Children’s Hospital of Eastern Ontario, University of Ottawa and a Pediatric Residency at McMaster Children’s Hospital, McMaster University.
Recent Publications
Poulin, KL, René, CA, Smith, IC, Vacratsis, PO, Burger, D, McMillan, HJ et al.. Extracellular vesicles as biomarkers of disease progression and therapeutic response in patients with spinal muscular atrophy. Mol Ther Adv. 2026.34 (2)201757 PMID:42232219
McMillan, HJ, Oskoui, M. Predicting Functional Decline in Duchenne Muscular Dystrophy: Advancing Trial Readiness and Patient Counseling. Neurology. 2026.106 (12)e214882 PMID:42190149
Wood, CL, Babalola, F, Benjamin, RW, Lam, C, McAdam, L, Nicolau, S et al.. Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. Muscle Nerve. 2026. PMID:42178495
Guridi, M, De Ford, C, See, CG, Murphy, AP, Chen, Y, Scharke, M et al.. Assessing biomarkers of bone metabolism and the role of the interleukin-6 signaling pathway in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2026.62 106414 PMID:41894885
Sbrocchi, AM, Kinnett, K, Lautatzis, ME, McMillan, HJ, Selby, KA, Veerapandiyan, A et al.. Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone. J Endocr Soc. 2026.10 (2)bvaf181 PMID:41509125
See more on PubMed